Home Blog Page 1430

Thai Researcher Turns Durian Peel Waste into High-Value Sustainable Fiber

By
Advertorial Desk
-

BANGKOK, Jan. 27, 2026 /PRNewswire/ — A doctoral graduate from Chulalongkorn University has developed Thailand’s first woven fiber made from discarded durian peels, transforming one of the country’s largest agricultural waste streams into high-value, sustainable fashion materials with global potential.

Thai Researcher Turns Durian Peel Waste into High-Value Sustainable Fiber
Thai Researcher Turns Durian Peel Waste into High-Value Sustainable Fiber

Dr. Usa Prachakul, a doctoral graduate from the Faculty of Fine and Applied Arts, Chulalongkorn University (Creative Arts – Fashion and Textiles), the creator of “Circular Textile Innovation from Durian Peel Waste to Anti-bacterial Clothing converts durian peel waste into textile fibers that offer higher breathability than pure silk and near-100 percent antibacterial properties. The material has been used to create fashion and lifestyle items under the brand MUW, which blends natural materials, art, and spiritual beliefs. The research received the Outstanding Award at the 2024 Thailand Research Expo, underscoring its scientific and commercial promise.

Thailand is the world’s largest producer of durian, with exports of fresh and processed products rising sharply in recent years—by nearly 488 percent. This growth, however, has intensified environmental pressures. Data from 2017 to 2021 show that durian peels generate about 146 million kilograms of waste annually, a figure that continues to increase. Most of this waste is currently disposed of through landfilling or open burning, practices that impose costs on farmers while contributing to pollution and long-term health risks for surrounding communities.

Seeking alternatives to burning and burial, the researcher focused on extracting value from durian peels through material science and sustainable design. The resulting fiber not only reduces waste but also offers functional advantages over conventional textiles, including natural antibacterial qualities and enhanced comfort, without relying on chemical treatments.

Beyond technical performance, the project aims to support Thailand’s soft power strategy by positioning sustainable Thai innovation on the global stage. By turning an abundant local by-product into premium fashion materials, the work connects environmental stewardship with creative industries and economic development.

The researcher said the project demonstrates how agricultural waste can be reimagined as a resource rather than a liability. By integrating scientific research with design and cultural storytelling, the durian-peel fiber shows potential for scaling up production, generating new income streams, and reducing the environmental footprint of Thailand’s booming durian industry.

As global demand grows for eco-friendly materials and circular-economy solutions, the durian-peel fiber highlights how locally grounded research can address environmental challenges while creating distinctive products for international markets.

Read the full article at: https://www.chula.ac.th/en/highlight/279133/

About Chulalongkorn University
Chulalongkorn University has made the world’s top 50 university list for employment outcomes, which reflects both the high employment rate and work ability of Chula graduates. The university is also listed as the best in Thailand for the 15th Consecutive Year (since 2009), according to the newly released QS World University Rankings 2024, putting Chula at 211th in the world, up from 244th last year.

Social Media:
Facebook: https://www.facebook.com/ChulalongkornUniversity
Youtube: https://www.youtube.com/chulauniversity
Linkedin: https://www.linkedin.com/school/15101896/

 

From Dream to Reality: Toshiba and Airbus Drive the Future of Hydrogen-Powered Flight with Superconducting Motors.

By
Advertorial Desk
-

SINGAPORE, Jan. 27, 2026 /PRNewswire/ — While the aviation sector rushes to achieve net-zero CO₂ emissions by 2050, innovations beyond the limits of sustainable aviation fuel remain essential. This is where Toshiba’s superconducting motor fits: a compact, lightweight, and high-output solution for electric propulsion systems. With less than one-tenth of the weight and size of conventional 2MW-class motors, such a drastic reduction in size and weight represents a game-changer in aviation, where every kilogram matters, and high output is required.


Experience the full interactive Multichannel News Release here: https://www.multivu.com/toshiba/9376851-en-toshiba-airbus-hydrogen-powered-superconducting-motors

Less than one-tenth the weight and smaller than other 2MW-class motors with the same output power
Less than one-tenth the weight and smaller than other 2MW-class motors with the same output power

Recognizing the promise of the prototype motor, first presented in 2022, the world’s largest aircraft manufacturer, Airbus, began collaborative research in 2024 to further develop and scale this technology. The joint signing of the partnership agreement at Japan International Aerospace Expo 2024 underlining both companies’ determination to promote aerospace innovation. Building on over 50 years of experience in superconducting technology, this partnership brings together Toshiba’s and Airbus’s innovations in hydrogen propulsion and aircraft electrification programs and marks a pivotal step toward realizing zero-emission flight.

An image of an aircraft equipped with a superconducting motor
An image of an aircraft equipped with a superconducting motor

Hydrogen-powered aircraft are set to transform air travel by replacing fossil fuels with clean energy solutions. Hydrogen can power aircraft in two ways: burning it in turbines or converting it to electricity in fuel cells. The second way is much more efficient, as it allows electric propulsion with zero CO₂ emissions. Toshiba’s superconducting motor amplifies this advantage by operating at cryogenic temperatures and, therefore, no electrical resistance, maximizing energy efficiency. Liquefied hydrogen stored at -253°C environment serves as both fuel and coolant, creating a perfect synergy that improves performance while reducing weight and paving the way for sustainable aviation.

Beyond aviation, Toshiba envisions superconducting motor technology as a powerful engine for sustainable mobility in various applications. Its lightweight, high-output design and cryogenic efficiency make it ideal for large-scale applications where weight and energy performance are critical. Potential future uses include powering next-generation ships for clean maritime transport and propulsion for space travel.

Toshiba combines technologies to achieve a greater good
Toshiba combines technologies to achieve a greater good

Toshiba and Airbus have taken a revolutionary path toward carbon-neutral skies, reshaping aviation with superconducting motors and hydrogen-powered propulsion systems. This collaboration goes beyond engineering; it embodies a vision of mobility free from carbon emissions while breaking through new efficiency frontiers. By pairing superconductivity with hydrogen’s potential as a clean energy source, the partnership is shaping a future where aircraft fly farther, cleaner, and smarter.


Achieving Carbon Neutrality in industries and transportation with Toshiba

Revenera Receives Frost & Sullivan’s 2026 Global Product Leadership Recognition for Excellence in Software Value Chain Enablement

By
Advertorial Desk
-

The company is recognized for its market-leading software monetization innovation, end-to-end life cycle enablement, and customer-centric product leadership.

SAN ANTONIO, Jan. 27, 2026 /PRNewswire/ — Frost & Sullivan is pleased to announce that Revenera has been awarded the 2026 Global Product Leadership Recognition in the software value chain enablement industry for its outstanding achievements in innovation, strategic execution, and customer impact. This recognition highlights Revenera’s consistent leadership in helping software producers navigate digital transformation, strengthen monetization strategies, and deliver measurable value across increasingly complex hybrid environments.

Frost & Sullivan evaluates companies through a rigorous benchmarking process across two core dimensions: business impact and product portfolio attributes. Revenera excelled in both, demonstrating its ability to align product innovation with evolving market demand while executing at scale with operational excellence. “With a comprehensive suite of solutions that span software monetization, installation, and composition analysis, Revenera empowers software producers to streamline operations, reduce risks, and unlock new revenue streams,” said Alaa Saayed, Vice President of Research – Digital Content at Frost & Sullivan.

Guided by a long-term growth strategy centered on platform innovation, customer partnerships, and continuous product evolution, Revenera has demonstrated strong agility in a rapidly transforming software economy. As organizations transition to cloud-native, subscription-based, and usage-driven models, Revenera’s sustained investment in software monetization, compliance intelligence, and life cycle transparency has enabled customers to scale efficiently across global markets.

Innovation remains central to Revenera’s approach. Its integrated portfolio supports the full software life cycle—from development and installation to delivery, monetization, and protection—addressing the needs of SaaS, on-premises, embedded, AI-enabled, and IoT-driven solutions. The platform enables flexible pricing models, granular usage intelligence, and entitlement enforcement that align revenue with customer value while mitigating operational and compliance risk.

“Revenera enables technology companies to monetize software across intelligent devices, on-premises software and cloud‑native apps—turning usage into revenue with flexible pricing, entitlement control, and deep analytics. Our customers launch faster, protect IP, and scale profitable growth across SaaS, embedded, and on‑premises deployments. We’re grateful for Frost & Sullivan’s recognition and proud to partner with customers for success,” said Nicole Segerer, SVP and General Manager, Revenera.

Revenera’s unwavering commitment to customer experience further reinforces its leadership position. Its modular, scalable architecture serves organizations of all sizes, from emerging software innovators to global enterprises, while integrating seamlessly with quote-to-cash ecosystems including billing, CRM, ERP, and subscription management systems. Through responsive support, localized expertise, and data-driven insights, Revenera continues to help customers reduce churn, improve renewals, and accelerate growth.

Frost & Sullivan commends Revenera for setting a high standard in product leadership, innovation execution, and market responsiveness. The company’s unified platform vision, deep monetization expertise, and customer-first culture are shaping the future of the software value chain enablement industry and delivering tangible, long-term results.
Each year, Frost & Sullivan presents the Product Leadership Recognition to a company that demonstrates outstanding product strategy and implementation, resulting in measurable improvements in market adoption, customer satisfaction, and competitive differentiation. The recognition honors organizations that are redefining their industries through innovation excellence.

Frost & Sullivan Best Practices awards recognize companies in regional and global markets for demonstrating outstanding achievement and superior performance in leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants through in-depth interviews, analyses, and extensive secondary research to identify best practices.

Frost & Sullivan Best Practices Recognition

Frost & Sullivan’s Best Practices Recognitions honor companies across regional and global markets that exhibit exceptional achievement and consistent excellence in areas such as leadership, technological innovation, customer experience, and strategic product development. Each recognition is the result of a rigorous analytical process in which Frost & Sullivan industry experts benchmark performance through comprehensive interviews, deep-dive analysis, and extensive secondary research. The goal is to identify true best-in-class organizations that are driving transformative growth and setting new industry standards.
Contact us: Start the discussion.

Contact:
Ashley Shreve
E: ashley.weinkauf@frost.com 

About Revenera

Revenera helps product executives build better products, accelerate time to value, and monetize what matters. Revenera’s leading solutions help software and technology companies drive top-line revenue with modern software monetization, understand usage and compliance with software usage analytics, empower the use of open source with software composition analysis, and deliver an excellent user experience—for embedded, on-premises, cloud, and SaaS products. To learn more, visit www.revenera.com.

Alphamab Oncology Announces the Results of a Phase III Clinical Study of Anbenitamab (KN026) were Published in Annals of Oncology

By
Advertorial Desk
-

SUZHOU, China, Jan. 27, 2026 /PRNewswire/ — Alphamab Oncology (Stock Code: 9966.HK) announced that the results from a phase III clinical study for the treatment of HER2-positive gastric or gastroesophageal junction cancer (GC/GEJ) of anbenitamab injection (KN026), independently developed by the Company and co-developed with JMT-Bio Technology Co., Ltd., a wholly-owned subsidiary of CSPC Pharmaceutical Group Co., Ltd. (stock code: 1093.HK), were recently published in the top-tier oncology journal Annals of Oncology (IF:65.4). The publication is titled: “Anbenitamab in previously treated HER2-positive gastric cancer (KC-WISE): pre-specified interim analysis of a randomized, phase III clinical trial”. The study was led by Professor Jianming Xu and his team from the Chinese PLA General Hospital as the principal investigators.

Annals of Oncology is the official journal of the European Society for Medical Oncology (ESMO) and the Japanese Society of Medical Oncology (JSMO). It is dedicated to publishing groundbreaking oncology and translational research that changes clinical practice and improves patient outcomes. With an outstanding impact factor of 65.4, the journal is committed to advancing the standards of cutting-edge research, accelerating the exploration of novel technologies, and facilitating their clinical application worldwide.

This study is a randomized, double-blind, controlled, multicenter Phase III clinical trial (NCT05427383) aiming at evaluating the efficacy and safety of anbenitamab combined with chemotherapy versus standard treatment in patients with HER2-positive GC/GEJ who had previously failed first-line therapy containing trastuzumab. The study enrolled patients with HER2-positive GC/GEJ who had disease progression after at least first-line trastuzumab-based treatment. Enrolled patients were randomized in a 1:1 ratio to receive either anbenitamab combined with chemotherapy (Anbenitamab Group) or standard-of-care therapy (SOC Control Group). Randomization was stratified according to the combined chemotherapy (taxane or irinotecan), HER2 expression (IHC 3+ or IHC 2+ with FISH amplification), and previous lines of therapy (1 or ≥2). The primary efficacy endpoints were progression-free survival (PFS) and overall survival (OS) assessed by an Independent Review Committee (IRC). Secondary endpoints included other efficacy measures such as objective response rate (ORR), duration of response (DoR), and disease control rate (DCR) as assessed by the IRC and investigators, investigator-assessed PFS, safety, and immunogenicity.

The study results (as of the cut-off date April 3, 2025) demonstrated that the Anbenitamab Group delivered highly encouraging outcomes:

  • Significant improvement in PFS: The Anbenitamab Group achieved a significantly prolonged median PFS. The median PFS was 7.1 months in the Anbenitamab Group versus 2.7 months in the SOC Control Group (HR 0.25, p<0.0001), representing a 75% reduction in the risk of disease progression or death.
  • Clinically meaningful survival benefit: In patients with second-line HER2-positive gastric cancer, the Anbenitamab Group achieved a median OS approaching 20 months for the first time. The median OS was 19.6 months and 11.5 months in the Anbenitamab and Control groups, respectively (HR 0.29, p<0.0001), corresponding to a 71% reduction in the risk of death.
  • Favorable safety and tolerability profile: The Anbenitamab Group exhibited a favorable tolerability profile. The incidence of treatment-emergent adverse events (TEAEs) was identical in both groups (97%). Importantly, despite a notably higher median treatment duration received in the Anbenitamab Group compared to the Control Group (6.5 cycles vs. 3.0 cycles), the incidence of grade ≥3 TEAEs was only slightly higher in the Anbenitamab Group (61% vs. 52%). The rates of serious adverse events (SAEs) and cardiac toxicity were comparable between the two groups. Furthermore, no treatment-related adverse events (TRAEs) leading to death occurred in the Anbenitamab Group.

In conclusion, the positive results robustly demonstrate that anbenitamab combined with chemotherapy has the potential to become a new standard of care for patients with HER2-positive gastric cancer who have failed at least one prior line of trastuzumab-containing therapy, and is well positioned to reshape the treatment landscape for second-line or later-line HER2-positive gastric cancer.

About Anbenitamab (KN026)

Anbenitamab (KN026) is an anti-HER2 bispecific antibody independently developed by Alphamab Oncology using the proprietary Fc-based heterodimer bispecific platform technology called CRIB (Charge Repulsion Induced Bispecific). Anbenitamab can simultaneously bind two non-overlapping epitopes of HER2, resulting in HER2 signal blockade. Through antibody-induced receptor clustering, it enhances ADCC and CDC effects while promoting the down-regulation of HER2 receptors on the cell surface.

In September 2025, the first New Drug Application (NDA) for anbenitamab injection has been accepted by the National Medical Products Administration (NMPA) for the treatment of HER2-positive gastric cancer (GC). Currently, several pivotal clinical trials of KN026 for second-line or above HER2-positive GC/gastroesophageal junction cancer (GEJ), first-line HER2-positive breast cancer (BC), neoadjuvant treatment of HER2-positive BC are being conducted.

Anbenitamab has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of HER2-positive or low expressing GC; it has been granted Breakthrough Therapy Designation by NMPA for the treatment of patients with HER2-positive GC/GEJ who have failed first-line standard treatment.

In August 2021, the Company entered an agreement with JMT-Bio Technology Co., Ltd. (“JMT-Bio”), a wholly-owned subsidiary of CSPC Pharmaceutical Group Co., Ltd. (“CSPC”) (stock code: 1093.HK), for the development and commercialization of KN026 in Mainland China. JMT-Bio was granted exclusive license rights of KN026 for the development and commercialization in the indications of BC an GC/GEJ in Mainland China (excluding Hong Kong, Macau and Taiwan).

About Alphamab Oncology

Alphamab Oncology (Stock Code: 9966.HK) is an innovative biopharmaceutical company focused on oncology. Leveraging proprietary platforms-including single-domain antibodies, bispecific antibodies, glycan-specific conjugation, linker-payloads, dual-payload ADCs, and high-concentration subcutaneous formulations, the Company has built a differentiated and globally competitive pipeline, covering cutting-edge candidates in ADCs, bispecific antibodies, and single-domain antibodies.

One product has received market approval: Envafolimab (KN035, brand name: 恩维达®), the world’s first subcutaneously injected PD-(L)1 inhibitor, offering greater convenience and accessibility in cancer treatment. The NMPA has accepted the new drug application for KN026 (Anbenitamab Injection), a HER2 bispecific antibody, for second-line or later HER2-positive gastric cancer. Four bispecific ADC candidates have entered clinical stages, and next-generation ADC pipelines — such as dual-payload ADCs — are advancing rapidly. The Company has established strategic partnerships with organizations including CSPC, ArriVent, and Glenmark, covering both product development and technology platforms.

Our overarching mission is to make cancer manageable and curable by addressing unmet clinical needs in oncology. Alphamab Oncology is continuously dedicated to the development of effective, safe, and globally competitive anti-tumor drugs, delivering China-innovated cancer therapies to benefit patients worldwide.

Railtown AI Technologies Launches Railengine, a Real-Time Event-Based Ingestion Engine to Power Next-Generation AI Agents

By
Advertorial Desk
-
Vancouver, British Columbia – Newsfile Corp. – January 26, 2026 – Railtown AI Technologies Inc. (CSE: RAIL) (OTCQB: RLAIF) (“Railtown”, “Railtown AI”, or the “Company”) a leader in AI developer tools and agentic frameworks, is pleased to announce the launch of Railengine, its real-time, event-based ingestion engine, a core component of the Company’s end-to-end AI agent development platform (the “Platform”). Railengine allows AI agents to ingest and act on streaming data in real time, advancing beyond traditional batch processing to deliver richer, context-aware insights and responses across complex enterprise environments. Combined with Railtown’s Railtracks Agent Development Kit (ADK) and Conductr agent observability tool, Railtown has produced a platform that enables developers to build, deploy, and manage intelligent AI agents at scale.

Railengine Provides agents instant access to context-rich, searchable enterprise knowledge, enabling developers to launch advanced RAG (Retrieval-Augmented Generation) workflows, automation, and agent runs while leveraging pre-built SaaS Data Connectors for seamless integration, semantic search, and intelligent automation. www.railengine.ai.

The Railtracks ADK offers developers a Python-native framework to design, orchestrate, and deploy autonomous AI agents with prebuilt integrations, execution tracing, and orchestration tools that support real world, multi-stage agent workflows. www.railtracks.org.

Conductr Railtown’s observability tool, provides developers and operations teams with end-to-end visibility into agent behaviour, performance metrics, resource utilization, and reasoning paths enabling debugging, optimization, and secure, efficient deployments. www.conductr.ai.

“With this launch, Railtown delivers a complete Agent Development Platform, from real-time data ingestion through agent creation and observability,” said Cory Brandolini, CEO of Railtown. “The Platform equips developers with the tools to build agents that act on live data streams while giving teams the insights and controls they need to operate with confidence.”

Strategic Integration with AI Partnerships and Canadian Sovereign AI Ecosystem

Building on Railtown’s acquisition of AI Partnerships Corp., the Company expects to integrate the Platform into the AI Partnerships global affiliate ecosystem, giving more than 180 AI solution provider affiliates access to Railtown’s tools to rapidly build and deploy production-ready AI agents across industries.

This integration will support Canadian sovereign computing and secure deployment, enabling affiliates and their customers to develop Canadian truly Sovereign AI Agents that meet stringent data residency, privacy, and compliance requirements while remaining fully controlled within Canada.

Canadian Compute and Hosting

The Railtown Platform, powered by TELUS’s sovereign GPU infrastructure and Uniserve’s hosting, provides developers with a complete, Canadian-resident environment for agent development.

By leveraging high-performance Canadian infrastructure, Railtown enables affiliates and their customers to deploy truly Sovereign AI Agents that meet stringent data residency, privacy, and compliance requirements.

Canadian Companies and Developers

In the combination of Railtown’s agent development platform, TELUS’ sovereign GPU infrastructure, and Uniserve’s Canadian hosting and managed services, will provide developers across Canada an end-to-end Canadian Sovereign AI Agent Development & Deployment Service, from data ingestion and agent design to secure compute, observability, and operational deployment. This ecosystem will support enterprise, government, and partner customers looking for secure, scalable, and sovereign AI solutions without reliance on foreign compute infrastructure.

The launch and ecosystem enhance Railtown’s ability to provide a scalable, production-ready foundation for industrial grade agentic AI unlocking broad access to innovative agent technologies while reinforcing Canada’s leadership in secure AI infrastructure and innovation.

About Railtown AI Technologies

Railtown AI Technologies Inc. builds AI developer tools and agentic frameworks that power the next generation of intelligent applications. Its Platform — including real-time ingestion (Railengine), agent development frameworks (Railtracks ADK), and advanced observability (Conductr) — helps teams build, deploy, and operate AI agents with confidence and at scale.

For more information, visit www.railtown.ai.

Follow us on social media

SUBSCRIBE FOR INVESTOR NEWS
Click here to receive our latest investor news alerts.

ON BEHALF OF THE BOARD
“Cory Brandolini”
Cory Brandolini, Chief Executive Officer

INVESTOR CONTACT
Rebecca Kerswell
Investor Relations Contact
Email: investors@railtown.ai
Phone: 1-604-417-4440

This news release contains forward-looking statements relating to the future operations of the Company and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will,” “may”, “should”, “intends”, “anticipates”, “expects” and similar expressions. All statements other than statements of historical fact included in this release, including, without limitation, statements regarding the future plans and objectives of the Company, the commencement of trading of the Company’s common shares on the CSE, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations are risks detailed from time to time in the filings made by the Company with securities regulators.

Readers are cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. As a result, the Company cannot guarantee that any forward-looking statement will materialize, and readers should not place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will only update or revise publicly any of the included forward-looking statements as expressly required by Canadian securities law.

The issuer is solely responsible for the content of this announcement.

ICP DAS-BMP at WHX Dubai 2026 Spotlights Low-Migration and Low-Friction TPU

By
Advertorial Desk
-

HSINCHU, Jan. 27, 2026 /PRNewswire/ — ICP DAS-BMP (Biomedical Polymers), a Taiwan-based manufacturer and supplier of medical-grade TPU (thermoplastic polyurethane), is pleased to announce its participation in WHX Dubai 2026 (formerly Arab Health), taking place from 9 to 12 February at the Dubai Exhibition Centre. Visitors can find the ICP DAS-BMP team at Booth S7C117.

Image by ICP DAS-BMP
Image by ICP DAS-BMP

The highlight of this year’s exhibit will be two TPU innovations addressing critical needs in medical device manufacturing: the Low-Migration Series and the Low-Friction Series.

The Low-Migration Arothane™ ARP-B20 TPU is ISO 10993 compliant and suitable for implantation up to 90 days. It minimizes additive migration during processing, helping catheters retain smooth surfaces throughout their shelf life, while offering multiple color options for flexible, customized designs.

The Low-Friction Series, engineered with an inherently smooth surface, eliminates the need for additional coatings or post-processing. Made entirely of TPU and free from PFAS or plasticizers, it delivers long-term stability without surface exudation or additive migration. Its low-friction properties suit applications requiring smooth insertion, such as nasogastric tubes with guidewires, while maintaining safety and performance during storage and use.

ICP DAS-BMP will also showcase a broad TPU portfolio for diverse medical applications. The ARP, ALP, and ALC series are suitable for devices classified as Limited (less than 24 hours), Prolonged (24 hours–30 days), and Long-term (more than 30 days) contact durations under ISO 10993-1. For radiopaque applications, ARP-B20 and ALC-B40 (qualified for 90-day implantation) and the ARP-W/WG series (40–60% tungsten) provide enhanced visibility for invasive or implantable devices. The Engineering Arothane™ EARP series, known for clarity and mechanical strength, is ideal for orthodontic components, Luer-Lock connectors, and other precision medical devices.

Together, these materials reflect ICP DAS-BMP’s commitment to advancing safer, reliable, and versatile TPU solutions, helping medical device manufacturers meet evolving healthcare needs.

About ICP DAS-BMP

ICP DAS-BMP, a leading TPU manufacturer and supplier based in Taiwan, is ISO 13485 certified and operates specialized laboratories focused on quality management. Leveraging over thirty years of industrial automation expertise from its parent company ICP DAS, ICP DAS-BMP employs smart factory practices to enhance product quality and expedite delivery times. The company is committed to responsive after-sales support and flexible solutions, even for small order quantities, ensuring customer satisfaction and fostering long-term partnerships.

For more information, please visit: https://bmp.icpdas.com

New “MedTech Advance” Sourcing Directory Launches to Streamline Global Medical Device Manufacturing

By
Advertorial Desk
-

Comprehensive e-book accelerates product development by connecting R&D and procurement teams with global suppliers.

TAICHUNG, Jan. 27, 2026 /PRNewswire/ — Today marks the official release of MedTech Advance, a comprehensive digital buyer’s directory engineered to accelerate the sourcing process for the medical technology industry. As the complexity of medical device design increases, MedTech Advance provides a centralized platform for Engineering, R&D, and Procurement professionals to discover elite suppliers and high-precision components.

MedTech Advance - sourcing medtech design and manufacturing suppliers
MedTech Advance – sourcing medtech design and manufacturing suppliers

“Speed-to-market is the primary challenge in MedTech today,” said Nick Yang, Manager of MedTech Advance. “We’ve built MedTech Advance to remove the friction from procurement, providing a vetted roadmap of partners capable of meeting the industry’s rigorous regulatory and technical demands.”

Featured Contributor: Protolis

The 2026 edition highlights specialized capabilities from industry leaders such as Protolis, a premier provider of rapid prototyping and low-volume manufacturing. Protolis brings critical expertise to the directory, offering high-precision plastic and metal components specifically for the life sciences sector.

By featuring contributors like Protolis—who utilize ISO 13485-certified processes and advanced technologies such as CNC machining, vacuum casting, and injection molding—MedTech Advance ensures that R&D teams can find partners capable of delivering functional prototypes and end-use parts that meet strict tolerances and aesthetic excellence.

Global Trade Show Distribution

The directory will receive massive international exposure through 2026, with distribution confirmed for the world’s leading medical trade fairs, including:

  • MEDICA & COMPAMED (Germany)
  • MD&M Series (USA)
  • Medtec Japan & Medtec China

The e-book is designed for high-impact roles in Engineering, R&D, Procurement, Quality Assurance, and Executive Management, serving the global medical device supply chain.

About MedTech Advance

MedTech Advance is a premier digital resource and global buyer’s directory dedicated to the medical device design and manufacturing industry. By providing a curated ecosystem of world-class suppliers, it empowers professionals to accelerate product development and optimize their supply chains.

Explore the e-book at medicaex.com

About Protolis

Protolis is a specialized rapid prototyping and low-volume manufacturing company, delivering high-precision plastic and metal components for the medical and life sciences industries. We combine advanced technologies such as CNC machining, vacuum casting, injection molding, and sheet metal fabrication to produce functional prototypes, small series, and end-use parts with exceptional quality and compliance. Our expertise extends to custom medical device enclosures, housings, and components requiring aesthetic excellence, strict tolerances, and ISO 13485-certified processes.

Learn more at protolis.com

REALTY ONE GROUP CELEBRATES 20 YEARS OF COMMUNITY IMPACT, REPORTS STRONG 2025 GIVING RESULTS

By
Advertorial Desk
-

LAGUNA NIGUEL, Calif., Jan. 27, 2026 /PRNewswire/ — Realty ONE Group International, a modern, purpose-driven lifestyle brand and one of the fastest-growing real estate franchisors in the world, today proudly announced its 2025 year-end giving results, highlighting the significant impact made by its real estate professionals around the globe, through ONE Cares, the company’s charitable foundation.

In 2025, the ONE Family Network supported 240,292 community neighbors, contributed 8,467 community service hours, and donated nearly $400,000 through ONE Cares initiatives, demonstrating the brand’s ongoing commitment to service, generosity, and community leadership.

“Giving back is not an initiative at Realty ONE Group, it’s the foundation of our 6C’s, our beliefs and our values,” said Kuba Jewgieniew, CEO and Founder of Realty ONE Group International. “Our professionals are committed to making a difference, not just in real estate, but in the communities they serve every day.”

Every year, Realty ONE Group International celebrates its founding on May 1 with a global day of giving and volunteering. That special day this year impacted nearly 60,000 lives with 3,053 volunteer hours and $144,785.

Reinforcing its commitment to sustainability, Realty ONE Group International pledged 1,069 trees in 2025, advancing its ONE Tree, ONE World initiative to nearly 142,000 trees pledged worldwide since 2022.

As the company continues to grow globally, Realty ONE Group remains focused on building a legacy defined by impact, purpose, and generosity.

Realty ONE Group International’s continued success is driven by its proprietary business systems, comprehensive coaching and support, bold lifestyle brand, and a people-first COOLTURE® that differentiates it from traditional real estate models. With more than 20,000 real estate professionals across 450+ locations in nearly 30 countries and territories, the brand continues to expand its global footprint while staying true to its mission of changing lives through real estate.

Learn more at www.OwnAOne.com or www.realtyonegroup.com

About Realty ONE Group International

Realty ONE Group International is one of the fastest growing, modern, purpose-driven lifestyle brands in real estate whose ONE Purpose is to open doors across the globe – ONE home, ONE dream, ONE life at a time. The organization has rapidly grown to more than 20,000 real estate professionals in over 450 locations across nearly 30 countries and territories because of its proven business model, full-service brokerages, dynamic COOLTURE, superior business coaching through ONE University, outstanding support and its proprietary technology, zONE. Realty ONE Group International has been named the number ONE real estate brand by Entrepreneur Magazine for three consecutive years and continues to surge ahead, opening doors, not only for its clients but for real estate professionals and franchise owners. To learn more, visit www.RealtyONEGroup.com.

1...1,4291,4301,431...6,709Page 1,430 of 6,709